ABOUT EDITAS MEDICINE
Pioneering the Possible
Editas Medicine is a pioneering gene editing company focused on developing transformative medicines, translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases.
Our corporate headquarters is located in Cambridge, MA, and we have a site in Boulder, CO.
Jump down to learn more about our work and the people who make it possible.
The Editas Medicine Mission
Our mission is to translate the power and potential of genome editing into a broad class of gene editing medicines that transform lives of people living with serious diseases.
What We’re Working On
We’re using CRISPR, a powerful genome editing technology to develop new gene edited medicines. We are researching and developing in vivo gene editing medicines, which edit genes inside the body.
Hear about some of our work featured in the news on NPR.
Dive into our work
Gene editing has the potential to change outcomes within a broad range of diseases. Right now, we’re concentrating our efforts on hemoglobinopathies and in vivo editing, including hematopoietic stem cells and other tissue types.
Blood diseases
Sickle cell disease (SCD), Beta thalassemia
Oncology
Advancing cellular therapy assets through partnerships, including continued development of alpha-beta T-cells medicines with Bristol-Myers-Squibb and gamma-delta T-cell medicines with Immatics N.V.
Executive Leadership
-
Gilmore O’Neill, M.B, M.M.Sc.,
President and Chief Executive Officer
-
-
Gilmore is President and Chief Executive Officer of Editas Medicine and a member of the Editas Board of Directors. He joined Editas Medicine in June 2022.
Gilmore brings to Editas more than 20 years of experience in genetic medicine, neurobiology, and clinical development. Gilmore also has a track record of driving and leading several of biotech’s most successful clinical programs and achieving marketing approvals for several medicines, including Amondys®, Vyondys®, Spinraza®, Plegridy®, and Tecfidera®.
Gilmore most recently served as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics. During his tenure at Sarepta, he led the R&D leadership team accountable across the value chain from creating and driving discovery, preclinical and clinical development, and global regulatory strategy of its RNA and gene therapeutic portfolio through to Medical Affairs support of the marketed products. Prior to that, Gilmore held several leadership roles at Biogen over a 15-year period, most recently serving as Senior Vice President responsible for all late-stage clinical development. During his tenure at Biogen, Gilmore oversaw development programs for rare disease, gene and cell therapy, neuromuscular disease, pain, multiple sclerosis, acute neurology, movement disorders, and Alzheimer’s disease.
Gilmore currently serves on the Board of Directors at UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging.
Gilmore received a Bachelor of Medicine degree from University College Dublin, a Master of Medical Sciences degree from Harvard University and completed his Neurology Residency training at Massachusetts General Hospital. He is licensed to practice medicine in the state of Massachusetts.
-
Linea Aspesi,
Executive Vice President and Chief Administration Officer
-
-
Linea is Executive Vice President and Chief Administration Officer at Editas Medicine. She joined Editas in February 2023, and is responsible for leading business operations, communications, and the people team. This includes developing and implementing the strategic vision in support of the mission and goals of the Company.
Linea is an influential human resources business executive and leader with more than 25 years of proven success defining, shaping, and implementing equitable, inclusive, and dynamic talent strategies for accelerated company growth that align to company vision, mission, and values.
Linea brings to Editas 15 years of experience in the life sciences sector, from discovery through commercialization, particularly in rare diseases, and has partnered with senior leaders to define and scale human capital strategies in areas including diversity, equity, and inclusion; employee experience, advocacy, and well-being; mergers and acquisitions; talent acquisition and retention; succession and performance planning; cultural innovation; transformation integration; and organizational design.
Linea joins Editas from Forma Therapeutics, a clinical-stage biopharmaceutical company focused on transforming the lives of patients with rare hematologic diseases and cancers. Linea served as Chief Human Resources Officer and successfully led the negotiations related to the people elements of the US $1B acquisition of Forma by Novo Nordisk in late 2022. Prior to joining Forma, Linea served as Saniona’s first Chief Human Resources Officer, where she established the HR value model and shaped a dynamic culture around the core value of “Put People First” to prepare the organization for commercial launch. Previously, she also served as Vice President and Head of Human Resources and Office Management for North America at Sobi, Inc. At Sobi, Linea focused on a significant expansion and acquisition strategy for the region, integrating more than 130 employees from the $2.5 billion acquisition of immunology therapy Synagis® from AstraZeneca, and building the commercial organization and capabilities in 90 days to launch Gamifant® to treat an ultra-rare genetic disease.
Earlier in her career, Linea held positions of increasing responsibility at Sanofi and Genzyme, including her most recent position as Head of Human Resources to the Industrial Affairs organization in North America. Here, she led an HR team of more than 25 HR practitioners and focused on manufacturing plant optimization, business development, and expansion. Additionally, Linea led the HR team supporting the Boston Hub R&D organization and Sanofi Genzyme, delivering strategic HR services for the launch of Kevzara® and Dupixent®, in the newly formed Immunology franchise in 2017.
Linea earned a Bachelor of Arts in Education from the University of Massachusetts, Amherst.
-
Brieana Buckley,
Senior Vice President, Development and Program Leadership
-
-
Brieana is Senior Vice President, Development and Program Leadership of Editas Medicine. She joined Editas Medicine in May 2023 and is responsible for leading program strategy and planning, including development activities related to Editas Medicine’s pipeline.
Brieana brings more than 20 years of experience in the healthcare and biotech industries. She has a deep understanding of global healthcare systems to address unmet needs and create access to novel medicines that transform patients’ lives. During her career in the pharmaceutical industry, she has demonstrated expertise in supporting all phases of clinical programs from first in human to commercial launch across multiple different disease areas, including neurology, hematology and rare genetic diseases. She has been an instrumental contributor to ten successful commercial product launches.
Brieana joined Editas Medicine from Rhythm Pharmaceutics where she served as Vice President of Medical Affairs. Her leadership was critical to the successful launch of the organization’s first commercial product. Prior to Rhythm, she was the Field Medical Lead of Rare Blood Disorders at Sanofi where she led teams responsible for building a highly successful franchise of therapies. Earlier in her career, Brieana held leadership positions with increasing responsibilities in medical affairs, market access, and health economics and outcomes research at Biogen.
Brieana holds a PharmD from the University of Utah. She completed her Managed Care Pharmacy Practice Residency at SelectHealth, an Intermountain Healthcare Company. She subsequently completed a Master of Pharmacoeconimics degree at the University of Florida.
-
Linda C. Burkly, Ph.D.,
Executive Vice President and
Chief Scientific Officer -
-
Linda is Chief Scientific Officer of Editas Medicine. She joined Editas Medicine in July 2023 and is responsible for leading the drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications.
Linda brings to Editas more than 35 years of experience in biotechnology as a research leader spanning the breadth of the drug discovery and development value chain in therapeutic areas of immunological, neurological, and rare genetic disorders. Linda also has a track record of contributing to the foundations of approved medicines and late-stage clinical candidates, including Trogarzo®, Tysabri®, and Dapirolizumab (currently in Phase 3 development), her role ranging across inventing therapeutic compositions, discovering novel pathway biology and uses of therapeutic compositions, co-authoring INDs, and leading project teams.
Prior to joining Editas, Linda held positions of increasing responsibility over a 37-year tenure at Biogen. She most recently served as Vice President and Senior Distinguished Investigator from 2014 to 2022. In this role, she led neuroscience-focused research teams in target identification to advancement, leveraging genetic and small molecule modalities to discover and develop differentiated medicines for genetic and neurodevelopmental disorders. Linda also developed disease area strategy and advanced programs in neuroinflammation as Head of Acute Neurology Research.
Earlier in her career, Linda led teams to discover and develop drugs for inflammatory and autoimmune diseases as Vice President and Senior Distinguished Investigator in Immunology. During this time, Linda invented a novel anti-CD4 mAb that was developed into Trogarzo®, discovered novel VLA-4/VCAM biology and uses of VLA-4 blockers including for Crohn’s disease, an indication of Tysabri®, and was Biogen lead on a partnered collaboration with UCB and therein an inventor of Dapirolizumab. Linda also devised an AAV Vector Immunogenicity and Toxicity Mitigation project, leading contributors across five functions to deliver solutions to mitigate toxicity and enable gene therapy development.
As a scientific innovator, Linda is an inventor on 17 issued U.S. patents. She is also a recognized scholar, featured in the Elsevier and Stanford University list of the top 2% of the most cited scientists worldwide cumulatively until August 2021, with 168 publications, including 144 peer-reviewed original papers.
Linda holds a Ph.D. from Tufts University Graduate School of Biomedical Sciences, Boston, MA, and a B.S. from Fairfield University. She completed a Postdoctoral Fellowship in the laboratory of Richard A. Flavell, Biogen Research Corp.
-
Damien Grierson,
Senior Vice President and Head of Legal
-
-
Damien is Senior Vice President, Head of Legal and Corporate Secretary of Editas Medicine. As Head of Legal, he oversees and manages all legal matters, including corporate governance, securities compliance and SEC reporting, partnering and licensing transactions, employment law matters, financings, and intellectual property strategy. He joined Editas Medicine in August 2020.
Damien has 20 years of combined in-house corporate and law firm experience. Prior to Editas, he served as Senior Counsel at a public healthcare company, where he was responsible for corporate governance and securities compliance. Earlier in his career, he was a Counsel in the Boston Office of K&L Gates LLP and an Associate at the Boston office of Cooley LLP and at the New York office of Shearman and Sterling LLP (now A&O Shearman).
Damien received a Juris Doctor degree from Vanderbilt University Law School and Bachelor of Arts degrees in economics and political science from the University of Tennessee, Knoxville.
-
Frank Panaccio,
Senior Vice President and Head of Business Development
-
-
Frank is Senior Vice President and Head of Business Development at Editas Medicine. He joined Editas in March 2022. As the Head of Business Development, he oversees and manages all business development activities, including partnerships, M&A, licensing, and strategic investments.
Frank is an experienced strategy, business development and corporate development executive with over 25 years of experience leading strategic growth initiatives, M&A, licensing transactions, and investments in the life sciences sector. Most recently, Frank served as Senior Vice President and Global Head of Mergers and Acquisitions at Lumanity and it’s predecessor company, where he was a member of the early founding team and led the company’s acquisition strategy. Prior to Lumanity, Frank was Senior Vice President of Strategy and Corporate Development at Parexel International, where he led the company’s strategic initiatives, M&A and partnership activity. Frank served at Parexel for six years and led key strategic initiatives, including the company’s $5B take-private transaction and the implementation of the company’s new growth strategy thereafter.
Frank also spent 15 years in various roles in venture capital, investment banking and strategy consulting at firms, including Fidelity Ventures and Jefferies, where he led investment activity, M&A execution and financial and strategic advisory services. In addition, Frank has held numerous board roles at various healthcare and IT companies and volunteers for a number of non-profit organizations.
Frank received a Bachelor of Arts in Economics degree from Harvard Colleage and earned his Master of Business Administration from Harvard Business School.
-
Amy Parison,
Senior Vice President and
Chief Financial Officer -
-
Amy Parison is Chief Financial Officer of Editas Medicine. She joined Editas Medicine in August 2022 and has served in multiple roles of increasing responsibility including Senior Vice President of Finance, Vice President of Finance, and Corporate Controller. Her strategic vision and leadership have been instrumental in steering key enterprise initiatives and fostering a culture of financial excellence.
Prior to her roles at Editas, Amy was the Corporate Controller at Rubius Therapeutics, Inc., a biotech that aimed to develop cellular medicines. At Rubius, she built and led the finance team following the Company’s IPO, and played a critical role in securing the Company’s equity and debt financings, and development of enterprise-wide business processes including financial processes and procedures. Over her seven-year career at Vertex Pharmaceuticals, Amy held various roles of increasing responsibility within the accounting and finance team, including supporting the Company’s business development efforts and international expansion of the finance and accounting teams. Amy began her career at PricewaterhouseCoopers, LLP, where she worked in audit.
Amy holds a Bachelor of Science and a Master of Accounting, both from Babson College.
-
Gregory Whitehead,
Executive Vice President and Chief Technical and Quality Officer
-
-
Greg is Executive Vice President and Chief Technical and Quality Officer at Editas Medicine. He joined Editas Medicine in October 2022 and is responsible for leading the Technical Development, Technical Operations, and Quality departments as the company advances its gene editing medicines towards biologics license applications (BLAs).
Greg has more than 25 years of experience in the biotech industry and extensive cell and gene therapy clinical and commercial development expertise. Prior to his current role, Greg served as Senior Vice President of Quality at Editas Medicine. Before joining Editas Medicine, Greg served as Chief Quality Officer at Rubius Therapeutics, establishing quality capabilities to support first-in-human clinical trials for genetically engineered red blood cells. Earlier in his career, he served as Vice President, Quality at bluebird bio. During his tenure at bluebird bio, Greg scaled the organization in support of multiple gene therapy clinical trials and commercial launch in the U.S. and Europe. Demonstrating strong leadership, Greg established a culture of quality dedicated to patient safety and data integrity. Prior to bluebird, Greg spent 10 years at Dendreon, in roles of escalating importance, most recently serving as Director, Corporate Quality. While at Dendreon, he established the corporate quality vision and mission and the company’s strategic roadmap for continuous improvement. He also led critical initiatives, including regulatory interactions and the successful transition from clinical to commercial production upon product approval.
Greg received his B.S. in forensic science from Michigan State University.
Board of Directors
Jessica is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She joined the Editas Medicine Board of Directors in February 2018 and served as Lead Independent Director. She was appointed Chair of the Board in December 2024.
Jessica also serves as a Director on the Board of Directors of Insulet Corporation and Maravai LifeSciences, Inc. She is a Trustee of The Rockefeller University. Jessica is also a strategic advisor to and investor in start-up healthcare firms.
Jessica is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she led work in strategy, R&D management, and marketing across pharmaceutical, biotech, medical-device, and consumer industries. She also held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing.
Jessica earned a BS from Yale College, an MBA from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in neuroscience/biochemistry from the Rockefeller University.
Bernadette Connaughton joined the Editas Medicine Board of Directors in October 2021. Bernadette is an accomplished pharmaceutical executive with more than 30 years of global strategic, commercial, and biopharmaceutical industry expertise.
Bernadette spent her career at Bristol Myers Squibb, building a consistent track record of achieving sales growth, improving operational models, and increasing profitability in the U.S., European, and Asian markets. She most recently served as President, Intercontinental. In this role, she developed successful, multi-year commercialization strategies for several oncology, virology, and immunology products.
Bernadette currently serves on the Board of Directors of Zealand Pharma A/S and Halozyme Therapeutics, Inc. She also serves on the Board of Trustees of the Boys and Girls Club of Mercer County, New Jersey. She was previously a member of the Board of Directors of Syneos Health, Inc., and Visterra, Inc.
Bernadette received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.
Andrew joined the Editas Medicine Board of Directors in May 2017 and holds more than 30 years of experience in a range of strategic and operating business roles, including more than 25 years in the biotech industry. Andrew currently serves as President, Chief Executive Officer and a member of the Board of Directors of C4 Therapeutics (C4T). Prior to C4T, Andrew served as Chief Financial Officer at Agios Pharmaceuticals, Inc., and as its Head of Corporate Development. Earlier in his career, Andrew served as President and Chief Executive Officer of BIND Therapeutics, Inc., and as Chief Financial Officer at Avila Therapeutics, Inc., until its acquisition by Celgene Corporation. He also held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team.
Andrew holds an MBA from the Tuck School at Dartmouth College and a BA in Economics from the University of Pennsylvania.
Elliott Levy, M.D., joined the Editas Medicine Board of Directors in April 2023. Elliott is an accomplished biopharmaceutical executive with more than 20 years of global research and development expertise, including leading clinical strategy and development for multiple programs at all stages of development at global biopharmaceutical companies Amgen and Bristol Myers Squibb.
Elliott served as Senior Vice President and Head of Global Development and R&D Strategy and Operations at Amgen from 2014-2021. Prior to Amgen, he was a Senior Vice President at Bristol Myers Squibb, where he held various R&D positions of increasing responsibility during his 17-year tenure at the company.
Elliott currently serves on the Board of Omega Therapeutics, Inc. and NuCana plc, both public biotechnology companies, and Kinaset Therapeutics. In addition, he is a Venture Partner at 5AM Venture Management, LLC, and a Senior Advisor at Boston Consulting Group.
Elliott received his B.A. in History from Yale College and an M.D. from the Yale School of Medicine, where he also completed fellowship training in internal medicine, nephrology, and clinical research.
Gilmore is President and Chief Executive Officer of Editas Medicine and a member of the Editas Board of Directors. He joined Editas Medicine in June 2022.
Gilmore brings to Editas more than 20 years of experience in genetic medicine, neurobiology, and clinical development. Gilmore also has a track record of driving and leading several of biotech’s most successful clinical programs and achieving marketing approvals for several medicines, including Amondys®, Vyondys®, Spinraza®, Plegridy®, and Tecfidera®.
Gilmore most recently served as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics. During his tenure at Sarepta, he led the R&D leadership team accountable across the value chain from creating and driving discovery, preclinical and clinical development, and global regulatory strategy of its RNA and gene therapeutic portfolio through to Medical Affairs support of the marketed products. Prior to that, Gilmore held several leadership roles at Biogen over a 15-year period, most recently serving as Senior Vice President responsible for all late-stage clinical development. During his tenure at Biogen, Gilmore oversaw development programs for rare disease, gene and cell therapy, neuromuscular disease, pain, multiple sclerosis, acute neurology, movement disorders, and Alzheimer’s disease.
Gilmore currently serves on the Board of Directors at UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, and at Aptinyx Inc., a biotechnology company developing therapies for the treatment of brain and nervous system disorders.
Gilmore received a Bachelor of Medicine degree from University College Dublin, a Master of Medical Sciences degree from Harvard University and completed his Neurology Residency training at Massachusetts General Hospital. He is licensed to practice medicine in the state of Massachusetts.
David joined the Editas Medicine Board of Directors in February 2019. He is a hematologist/oncologist and an expert in stem-cell biology and blood malignancies. He is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute. He is chairman emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. David has published more than 350 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem-cell function.
David is the recipient of numerous honors, including elected membership of the National Academy of Medicine and the American Academy of Arts and Sciences, a fellowship at the American College of Physicians and at the American Association for the Advancement of Science, and awards from the American Society of Hematology, the International Society for Experimental Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Wellcome Fund, and the Leukemia and Lymphoma Society. He has served on the board of scientific counselors for the National Cancer Institute; the board of external experts for the National Heart, Lung and Blood Institute; the board of directors of the International Society for Stem Cell Research; and is an affiliate member of the Broad Institute of Harvard and MIT. He also serves on multiple editorial boards, scientific advisory boards, and corporate boards. He is a scientific founder of Fate Therapeutics, Inc., Magenta Therapeutics, Inc., and Garuda Therapeutics. David also serves on the board of directors of Agios, LifeVault Bio, and Clear Creek Bio, Inc.
David is a graduate of Bucknell University (B.A.) and Case Western Reserve University (M.D.) with honorary degrees awarded from Harvard University (A.M.), Bucknell University (Sc.D.), Case Western Reserve University (Sc.D.) and Lund University in Sweden (M.D.). He serves as a Visiting Scholar to Pembroke College, University of Cambridge, U.K.
Our Scientific Founders
Core Member, Broad Institute of MIT and Harvard; Investigator, McGovern Institute for Brain Research, Massachusetts Institute for Technology; W.M. Keck Career Development Professor, Departments of Brain and Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology; Robertson Investigator, New York Stem Cell Foundation
Feng joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. He is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Feng is a Searle Scholar and has received both a Director’s Transformative Research Award and a Director’s Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics.
Feng holds an AB degree in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.
Professor of Genetics, Health Sciences and Technology, Harvard University and MIT; Director of the HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute and Wyss Harvard Institute of Biologically Inspired Engineering
George is a leading expert in human genetics and biotechnology. He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT). He is also director of the US Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. George helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. George has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008.
George holds a Ph.D. in biochemistry and molecular biology from Harvard University and a BA in zoology and chemistry from Duke University.
Keith currently serves as professor of pathology at Harvard Medical School and is associate chief of pathology for research and the Jim and Ann Orr Research Scholar at Massachusetts General Hospital (MGH). He is also a member of the Center for Cancer Research and Center for Computational and Integrative Biology at MGH.
Keith has been a pioneer in the development of important technologies for targeted gene editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals.
Keith holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School, and an AB degree in biochemical sciences from Harvard College.
David is an accomplished chemist, biologist, and innovator. He currently serves as professor of chemistry and chemical biology at Harvard University, investigator of the Howard Hughes Medical Institute, and vice-chair of the faculty and core institute member of the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT). His research has advanced the fields of therapeutics discovery, laboratory evolution, macromolecular delivery, and gene editing. David’s insight and breadth led him to be tapped to serve as a JASON, an elite group of scientists who advise the US government on matters of science and technology. He is also the recipient of numerous scientific distinctions, including the American Chemical Society Pure Chemistry and Arthur C. Cope Young Scholar Awards, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the National Science Foundation Faculty Early Career Development Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award, and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. David was named to the Popular Science “Brilliant 10” for young scientists in the US, as well as to the MIT TR100 for young innovators. In 2016 he was named one of the Top 20 Translational Researchers by Nature Biotechnology. His accomplishments also include groundbreaking research leading to the foundation of Ensemble Therapeutics and Permeon Biologics.
David holds a BA degree in chemistry from Harvard College and a Ph.D. in organic chemistry from the University of California, Berkeley.